Zai Collaborates with Geneseeq to Implement Personalized Cancer Care
publication date: Oct 14, 2021
Zai Lab of Shanghai will collaborate with Geneseeq Technology, a Toronto-China company, to integrate cutting-edge NGS services into clinical trials and advance precision care. The two companies will form business relationships based on Geneseeq's clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing services for Zai's cancer candidates. Zai has three cancer products approved in China and another 10-15 candidates in development, many of them based on companion biomarkers. More details....
Stock Symbol: (NSDQ: ZLAB; HK: 9688)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.